Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages

Bartneck, Matthias; Peters, Franziska Marie; Warzecha, Klaudia Theresa; Bienert, Michaela; Bloois, Louis van; Trautwein, Christian; Lammers, Twan; Tacke, Frank

doi:10.1016/j.nano.2014.02.011

Cited by 80 publications

(83 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surprisingly, T cells were the most affected cell type by flow cytometric analysis, while Kupffer cells even increased due to the treatment with Dex liposomes (Fig. 6(E)), coherent with earlier findings of a mild activation of human terminally differentiated macrophages after incubation with Dex liposomes [4]. The Dex liposomes led to a pronounced increase in the number of CD301 þ iMF (Fig.…”

Section: Treatment Of Chronic Liver Injury and Fibrosis Using Dex Lipsupporting

confidence: 90%

“…Liposomal drug delivery is also considered to be potentially beneficial for the treatment of inflammatory diseases [2], because the systemic administration of anti-inflammatory drugs regularly results in systemic immunosuppression rendering patients susceptible for infections such as sepsis [3]. We have previously shown that liposomal encapsulation of the anti-inflammatory drug dexamethasone allows for a reduction of unspecific effects of the encapsulated compounds on human primary cells [4].…”

Section: Introductionmentioning

confidence: 99%

“…We have recently demonstrated that liposomes loaded with the corticosteroid dexamethasone block migratory and inflammatory functions of primary human macrophages in vitro [4]. We now investigated the effects of liposomal encapsulated dexamethasone on macrophages and other immune cell populations in vivo.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases

et al. 2015

Self Cite

View full text Add to dashboard Cite

Section: Treatment Of Chronic Liver Injury and Fibrosis Using Dex Lipsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…Moreover, newly developed different liposomal combinations/formulations and liposomal vaccines have shown promising results in clinical studies and in commercial applications. In all, liposomal formulations are still important and potential tool for its clinical application of nanomedicines [45,50,61,63,65,.…”

Section: Discussionmentioning

confidence: 99%

“…Corticosteroid, dexamethasone-loaded liposomes have been reported to specifically reduce cytotoxicity in human fibroblasts and macrophages, with downregulation of proinflammatory cytokines like tumor necrosis factor (TNF), interleukin (IL)1β, reduced migration of monocytes and macrophages in inflamed conditions thereby suggesting their efficient applicability and nontoxic role in patients suffering from rheumatoid arthritis, atherosclerosis, colitis, and cancer [50]. Nanomedicine-based strategies are being employed in targeting of atherosclerosis [51].…”

Section: Inflammatory Diseasesmentioning

confidence: 99%

Multidynamic Liposomes in Nanomedicine: Technology, Biology, Applications, and Disease Targeting

Ghosh

Ansar²

2014

Nanoparticles' Promises and Risks

View full text Add to dashboard Cite

Biocompatible and biodegradable liposome nanomedicine are finding large-scale application in delivery of drugs, RNA, antisense oligonucleotides, DNA, plasmids carrying gene, antioxidants to targeted sites for diagnosis, and treatment at cellular and molecular level of disease both in human and livestock.Conventional drug delivery system suffers from the disadvantage of narrow therapeutic index, poor serum solubility, and nonspecific target effects. Circumventing this problem, liposome drug nanoparticles are designed with the advantage of enhanced permeability, retention effect, selective targeted delivery, stimuli-induced release that can evade the host defense system, cross the bloodbrain barrier, thus conferring, synergetic effects, small interfering RNA (siRNA) co-delivery, multimodality therapies, and oral delivery of therapeutics at disease sites. Liposomes with diverse range of modifications are being designed to generate improvised medicine delivery systems. Immuno-liposomes, linked with antibodies are promising tools for targeted drug delivery to specific cancer cells. In the recent times several anti-cancer agents in nanodelivery systems are under preclinical and clinical studies. Lipid-based liposomal delivery systems of self-amplifying RNA vaccines are showing promising effects.Globally research is being carried out in generating liposomes with higher compatibility within the biological system in targeting a wide array of diseases including cancer, overcoming multidrug resistance, inflammatory diseases, thrombosis, psoriasis, muscular dystrophy, spinal cord injury, neurologic diseases, diabetes, parasite induced diseases, and cardiovascular diseases.

show abstract

Targeting and Modulation of Liver Myeloid Immune Cells by Hard‐Shell Microbubbles

et al. 2018

Self Cite

View full text Add to dashboard Cite

Poly -butylcyanoacrylate (PBCA)-based hard-shell microbubbles (MB) have manifold biomedical applications, including targeted drug delivery or contrast agents for ultrasound (US)-based liver imaging. MB and their fragments accumulate in phagocytes, especially in the liver, but it is unclear if MB affect the function of these immune cells. We herein show that human primary monocytes internalize different PBCA-MB by phagocytosis, which transiently inhibits monocyte migration in vertical chemotaxis assays and renders monocytes susceptible to cytotoxic effects of MB during US-guided destruction. Conversely, human macrophage viability and function, including cytokine release and polarization, remain unaffected after MB uptake. After i.v. injection in mice, MB predominantly accumulate in liver, especially in hepatic phagocytes (monocytes and Kupffer cells). Despite efficiently targeting myeloid immune cells in liver, MB or MB after US-elicited burst do not cause overt hepatotoxicity or inflammation. Furthermore, MB application with or without US-guided burst does not aggravate the course of experimental liver injury in mice or the inflammatory response to liver injury. In conclusion, PBCA-MB have immunomodulatory effects on primary human myeloid cells , but do not provoke hepatotoxicity, inflammation or altered response to liver injury, suggesting the safety of these MB for diagnostic and therapeutic purposes.

show abstract

Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages

Cited by 80 publications

References 31 publications

Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases

Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases

Multidynamic Liposomes in Nanomedicine: Technology, Biology, Applications, and Disease Targeting

Targeting and Modulation of Liver Myeloid Immune Cells by Hard‐Shell Microbubbles

Contact Info

Product

Resources

About